DRCMDA: A Dual-View Drug Repositioning Framework with Cluster-Aware Structured Masked Reconstruction and Diffusion-Based Metapath-Graph Augmentation.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42721169.
- Also identified by DOI 10.1109/JBHI.2026.3732933.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Drug repositioning aims to identify new therapeutic indications for existing drugs, yet current deep learning approaches on multi-source biological data face limitations in both homogeneous and heterogeneous network modeling. In homogeneous similarity networks, random masking-based self-supervised learning neglects intrinsic clustering structures of biological entities and fails to capture high-order semantics, while in heterogeneous networks, sparse associations limit the effectiveness of metapath-based reasoning. To address these challenges, we propose DRCMDA, a dual-view drug repositioning framework that combines cluster-aware structured masked reconstruction with diffusion-based metapath-graph augmentation. The homogeneous module employs cluster-guided column permutation perturbations and a Teacher-Student distillation mechanism to learn robust, high-level representations, while the heterogeneous module leverages a diffusion model to generate diverse synthetic metapath graphs from the learned graph distribution. Furthermore, DRCMDA employs dual-view contrastive learning and node-level feature fusion to align and integrate complementary information across homogeneous and heterogeneous views. Experiments on three benchmark datasets demonstrate that DRCMDA consistently outperforms state-of-the-art methods across multiple evaluation metrics, with case studies and molecular docking analyses confirming its translational potential in identifying promising therapeutic candidates.